Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tegaderm CHG is a transparent intravenous (IV) securement dressing that integrates a chlorhexidine gluconate (CHG) gel pad within a breathable film dressing. The product is designed to cover and protect catheter sites and secure devices to the skin while providing immediate and continuous antimicrobial protection for up to 7 days. The integrated gel pad contains 2% w/w chlorhexidine gluconate, an antiseptic agent with broad-spectrum antibacterial and antifungal activity. This combination reduces catheter-related bloodstream infections (CRBSI) and vascular catheter colonization by suppressing regrowth of microorganisms commonly associated with these infections. The transparent film acts as a waterproof barrier against external contaminants, including bacteria, viruses (27 nm or larger), yeast, and fluids, while allowing continuous site observation[1][3][6]. Clinical studies have shown that use of this dressing significantly reduces CRBSI rates compared to standard dressings but may increase the incidence of contact dermatitis[5][6]. It is not indicated for use on premature infants or infants younger than two months due to risk of hypersensitivity reactions or necrosis[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tegaderm CHG.